Oncoinvent ASA (OSL:ONCIN) Interest Expense: kr-0.02 Mil (TTM As of Dec. 2025)


OSL:ONCIN Oncoinvent ASA OSL:ONCIN
37 GF Score
Price kr66.00
GF Value kr973.15
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Interest Expense?

Oncoinvent ASA OSL:ONCIN +14.58% 37 Interest Expense is kr-0.02 Mil as of Dec. 2025. GuruFocus rates OSL:ONCIN with a GF Score™ of 37/100 and a GF Value™ of kr973.15 (Possible Value Trap). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oncoinvent ASA's interest expense for the six months ended in Dec. 2025 was kr 2.71 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oncoinvent ASA's Operating Income for the six months ended in Dec. 2025 was kr -84.68 Mil. Oncoinvent ASA's Interest Expense for the six months ended in Dec. 2025 was kr 2.71 Mil. Oncoinvent ASA did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncoinvent ASA  (OSL:ONCIN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncoinvent ASA's Interest Expense for the six months ended in Dec. 2025 was kr2.71 Mil. Its Operating Income for the six months ended in Dec. 2025 was kr-84.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was kr0.68 Mil.

Oncoinvent ASA's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Oncoinvent ASA Interest Expense Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Interest Expense Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.32 -0.58 -0.08 -0.02

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.19 -2.07 1.99 -2.73 2.71
OSL:ONCIN
37GF Score
Oncoinvent ASA OSL:ONCIN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-0.02 Mil mean?
Oncoinvent ASA (OSL:ONCIN) has a Interest Expense of kr-0.02 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Interest Expense too high?
Oncoinvent ASA's current Interest Expense is kr-0.02 Mil. Overall, Oncoinvent ASA has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Interest Expense compare to VRTX and REGN?
Oncoinvent ASA's Interest Expense of kr-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Interest Expense is kr-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr973.15, compared to a current price of kr66.00 — trading 93.2% below its estimated fair value. The current Interest Expense is kr-0.02 Mil. Oncoinvent ASA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current Interest Expense is kr-0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr973.15. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for OSL:ONCIN:

  • Interest Expense: kr-0.02 Mil
  • GF Value™: kr973.15 vs. price of kr66.00 (93.2% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges 0RU5:UK7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score

Get the complete analysis for OSL:ONCIN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr66.00
Price
kr973.15
GF Value